These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8064788)

  • 1. Clinical pharmacology of converting enzyme inhibitors, calcium channel blockers and diuretics.
    Sinaiko AR
    J Hum Hypertens; 1994 May; 8(5):389-94. PubMed ID: 8064788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
    Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of antihypertensive therapy on renal function.
    Rappelli A; Baldinelli A; Zingaretti O; Espinosa E; Salvi S; Fulgheri PD
    J Hypertens Suppl; 1991 Dec; 9(3):S37-40. PubMed ID: 1686783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed dose combinations of ACE inhibitors.
    Rangoonwala B; Schulz W; Bauer B
    Br J Clin Pract; 1996 Dec; 50(8):454-65. PubMed ID: 9039718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy.
    Deedwania PC
    Cardiol Clin; 2005 May; 23(2):139-52. PubMed ID: 15694743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
    Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive persistence and drug class.
    Marentette MA; Gerth WC; Billings DK; Zarnke KB
    Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological hypertension therapy].
    Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
    Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.